Peptide Decoding
New?New to peptides?Start here →
Decoding

Pep19 (WATACAP)_Dosage, benefits & legal status

Also known as WATACAP, Pep-19, PEP19, RMH PEP19, DIIADDEPLT, white adipose tissue activator cyclophilin A peptide

Published November 19, 2026

An oral ten-residue CB1 blocker with two company-funded trials that disagree about weight.

Reduce visceral fatSynthetic decapeptide, peripheral CB1 inverse agonist (oral)Supplement
Dose2 to 10 mg once daily at bedtime (trials)
FrequencyOnce daily at bedtime
RouteBy mouth (oral capsule)
StatusSupplement
CycledTaken continuously, once nightly

See how this dose compares across the library →

01

What is Pep19 (WATACAP)?

Plain language first. The technical label stays, but it never stands alone.

Overview

A capsule peptide aimed at the fat around your organs rather than at your appetite.

The technical version

An orally administered synthetic decapeptide acting as a peripherally restricted CB1 inverse agonist, studied for visceral adiposity and insulin sensitivity.

What it's used for

An oral capsule marketed for visceral fat, insulin sensitivity and sleep quality.

02

How does Pep19 (WATACAP) work?

What it does in the body, and where.

Pep19 is ten amino acids, DIIADDEPLT, and it is a deliberately altered copy of something the body makes. The natural peptide is DITADDEPLT, a fragment of cyclophilin A, and researchers changed the third residue from threonine to isoleucine to sharpen its activity at the CB1 receptor. That single change is why the molecule exists, and it is also why calling it naturally occurring is not accurate.

  1. 01
    It blocks CB1, the receptor cannabis acts on
    CB1 is the receptor behind the appetite effects of cannabis. Blocking it was a real pharmaceutical strategy for obesity until rimonabant was withdrawn in Europe in 2008 over psychiatric harms. Pep19 is an inverse agonist at the same receptor, which means it pushes the receptor below its resting activity rather than merely getting in the way.
  2. 02
    The design point is that it stays out of the brain
    Rimonabant's problem was central. A peptide this size and this charged is a poor candidate for crossing into the brain, and the 2017 paper that named Pep19 reported no central nervous system effects in animals at doses that changed fat tissue. That is the entire case for the molecule, and it rests on animal work.
  3. 03
    In fat cells it turns up UCP1
    In cultured fat cells and in animal white fat, Pep19 raised uncoupling protein 1, the protein that lets brown fat burn energy as heat instead of storing it. The effect was blocked by a CB1 antagonist, which is the evidence that it works through that receptor. It also switched on the pERK1/2 and AKT signaling pathways.
  4. 04
    What that adds up to in people
    Two small randomized trials, both company-funded. The first found visceral fat down 17 percent at 5 mg over 60 days, with body weight and waist circumference also falling. The second, larger and longer, was framed around improving fat distribution and insulin sensitivity independently of weight loss. Read together, the company's own trials do not agree on whether the scale moves.
Anatomical illustration highlighting the whole body
WHAT THIS COMPOUND ACTS ON:
03

What else is it used for?

Each use below carries its own evidence level. Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.

  • Visceral fat reduction, the outcome both randomized trials were built aroundpeer-reviewed-human
  • Insulin sensitivity and glycemic control, the headline of the 90-day trialpeer-reviewed-human
  • Sleep quality, significant in the 60-day trial and weaker on repeatpeer-reviewed-human
  • Fatty liver disease, the subject of a registered Brazilian trial with no results publishednone

The published record

Research index

3

Papers about Pep19 (WATACAP) · this compound only

Searched: WATACAP, DIIADDEPLT.

Left out: DITADDEPLT (the natural peptide this one was modified from, which differs at one residue); Pep19 (also an older name for a neuronal protein, so it returns unrelated research); PEP-19 (an established name for the neuronal protein PCP4); PEP19 unhyphenated (the same clash without the hyphen, and the search ignores capitals); PCP4 (that neuronal protein's gene name); calmodulin (the protein PCP4 binds, with a large literature of its own); cyclophilin A (the parent protein, with a very large literature of its own); peptidyl-prolyl cis-trans isomerase A (the same protein's formal name); hemopressin (a related peptide that acts on the same receptor, a different molecule); rimonabant (a withdrawn drug acting on the same receptor, a different molecule); CB1 (the receptor it acts on, with one of the largest literatures in pharmacology); cannabinoid receptor (the same receptor, written out); intracellular peptide (the whole research field this peptide came from); UCP1 (a protein used as a marker in the laboratory work, with its own literature); pep19 as a bare enumeration (some papers use pep19 simply as a numbered label in a list); RMH (three letters from a commercial name); 1536481-46-5 (the CAS number, which does not appear in paper titles or abstracts); Nutroslim (a commercial name).

2 papers tagged human · 1 not reviews or lab · 1 clinical trial publications

1 registered trials · none with posted results

Furthest stage reached: Published trials only, 1 clinical trial publication, no phased trial registered

Compare this against the whole library →

In animals3
In the lab0
Reviews0
Senior author shareSpread across many groups

Evidence summary

Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. A preprint and its journal version count once.

Pep19 (WATACAP) vial rendering
Compound field notes

At a glance

Four things to know about Pep19 (WATACAP)

01

Evidence

Supplement

02

Category

Weight loss and metabolic

03

Common vial

Varies

04

Half-life

Not published

04

How much, and do you cycle it?

The range, and whether you take breaks.

2 to 10 mg once daily at bedtime (trials), once daily at bedtime. Taken continuously, once nightly Trial dose

Both trials dosed every night without a break, for 60 and 90 days. Nothing longer has been published, so there is no evidence either way about what happens past three months.

Compare this against the whole library →

05

How long does it stay in the body?

The half-life, and where the figure comes from.

Not publishedNo figure

No pharmacokinetic study in people has been published. That matters more than usual for this compound, because the whole premise is that it is orally active and stays out of the brain, and both of those are pharmacokinetic claims. The published support is animal work and the absence of central effects in those animals, not measured human exposure.

You can compare this against the whole library to see where it sits.

06

What does it cost?

Typical dose and cost, in plain numbers.

Pep19 (WATACAP) is not injected in the forms covered here

It is taken by mouth (oral capsule). Every published human dose is an oral capsule taken once daily at bedtime. The 60-day trial used 2 mg or 5 mg against placebo in 24 people, split one to one to one. The 90-day trial used 5 mg or 10 mg against placebo in 56 people. What is sold commercially is a 5 mg capsule, and the developer now describes a 10 mg capsule as the product. The capsules used in the first trial were made as a dietary supplement by the same commercial operation that markets them, which the paper discloses in its methods. A trade registry entry states the ingredient was self-affirmed as safe at up to 3.8 grams a day, a figure roughly four hundred times the largest dose any trial has used, and that number describes a safety ceiling rather than a dose anyone has taken.

Cost per month
—
Cost per dose
—
Typical dose
2 mg–10 mg / dayHuman study
07

How do you store it?

Before mixing, and after.

Room temperature. Cool, dry, out of light.

Pep19 (WATACAP) is taken as a pill or capsule. Keep it in its original container at room temperature, away from heat, humidity, and direct sun. No fridge or mixing needed. Check the expiration date on the bottle.

08

What are the side effects and cautions?

Known cautions and warnings for this compound.

Solubility, computed: 60% charged residues, 50% hydrophobic. Water usually sufficient.

A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.

Who should avoid it

Check these before anything else.
  • Pregnancy or breastfeeding, where no data exist
  • A history of depression or suicidal thinking, because the drug class it belongs to has a record there and this peptide has not been studied in anyone with that history
  • Anyone expecting the weight loss seen with a GLP-1 drug, because the larger trial was explicitly designed around benefit without weight loss

Stop and get help

These are emergencies. Seek care.
  • New or worsening low mood, hopelessness or thoughts of self-harm
  • Any allergic reaction, meaning rash, swelling of the face or lips, or trouble breathing
  • Persistent vomiting or severe abdominal pain

Common effects

Expected, and usually mild.
  • No adverse events were attributed to Pep19 in either randomized trial.
  • Sleep quality improved in the first trial at both doses, and the finding did not hold up as robustly in the second.

Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.

09

Is Pep19 (WATACAP) approved?

And where the numbers on this page come from.

Not as a medicine. Pep19 (WATACAP) is sold without a prescription as a supplement, which is a different thing from being approved as a drug.

What has happened recently

Not a drug and not approved as one. It is sold in the United States as a dietary supplement, and the only regulatory status its developer claims is self-affirmed GRAS, dated 2022 on the developer's own page. Self-affirmation means a panel the company assembled concluded the ingredient is generally recognized as safe; it involves no FDA review, no FDA agreement and no public docket unless the company separately files a GRAS notice. No FDA GRAS notice inventory entry for this ingredient was located during this review. The developer's page also describes the compound as FDA-recognized in the same section as the self-affirmed claim, and those are different things. A separate statement reported in trade press is that the company notified the FDA regarding structure and function claims, which is the routine supplement notification route under the Dietary Supplement Health and Education Act and is not an approval or an endorsement. Nothing here has been assessed by FDA for efficacy.

Guides for this compound

Sources

  • Heimann et al., A novel peptide that improves metabolic parameters without adverse central nervous system effects, Scientific Reports 7, article 15009(2017)
    The paper that created and named this peptide, and the reason the naturally occurring claim fails. Conformational-sensitive antibodies were used to screen intracellular peptides for activity at G protein coupled receptors. One hit, DITADDEPLT, derived from peptidyl-prolyl cis-trans isomerase A, better known as cyclophilin A, activated CB1. The authors then state that this original sequence was rationally modified to improve CB1 inverse agonist activity, producing DIIADDEPLT, which they named Pep19. Pep19 displaced radioligand binding at CB1 with an IC50 near 4.9 times ten to the minus twelve molar, induced uncoupling protein 1 in both white adipose tissue and cultured adipocytes, and activated pERK1/2 and AKT. The uncoupling protein 1 effect was blocked by the CB1 antagonist AM251. The title's claim is that it improves metabolic parameters without adverse central nervous system effects.
  • Heimann, Krongrad et al., Pep19: A Novel Approach for Reducing Visceral Fat and Improving Sleep Quality in Obese Adults, Results From an Early-Stage Clinical Trial, Diabetes/Metabolism Research and Reviews, doi 10.1002/dmrr.70056(2025)
    The first randomized human trial, read for its design and its numbers. Twenty-four subjects, twelve male and twelve female, aged 46 to 59, weighing 91 to 106 kg, body mass index 30 to 35, assigned one to one to one to placebo, 2 mg Pep19 or 5 mg Pep19, taken orally once daily at bedtime for 60 days, described by the authors as triple-blinded. In the 5 mg group visceral fat fell 17 plus or minus 4.7 percent with no change in lean mass, and body weight and waist circumference also fell significantly. Sleep quality improved by 35 plus or minus 10 percent at 2 mg and 25 plus or minus 16 percent at 5 mg. The methods give the CAS number as 1536481-46-5 and expand WATACAP as white adipose tissue activator cyclophilin A peptide. The same section describes Pep19 as a natural peptide synthetically produced, which is the phrasing the 2017 paper contradicts. The study was funded by the company and the corresponding authors are company staff. A companion dog study is cited in which eight beagles received 5 mg a day, 0.32 to 0.49 mg per kg, for 28 days with no adverse effects.
  • Vantini, Roberto de Sa, Fonseca et al., Effects of Pep19 on adipose tissue distribution and metabolic parameters in adults with obesity: A randomized, double-blind, placebo-controlled trial, iScience 29(10):117471, October 16, 2026(2026)
    The second and larger randomized trial, which reframes the claim. Fifty-six adults with obesity received oral placebo, 5 mg or 10 mg Pep19, one capsule daily at bedtime for 90 days, with group sizes of roughly 16, 19 and 18. The stated question is whether modulating where fat sits can improve insulin sensitivity independently of weight loss. Reported findings are a greater reduction in the android to gynoid fat ratio at 10 mg versus placebo, improved insulin sensitivity and glycemic control, preserved lean mass and a favorable 90-day safety profile. The sleep result from the earlier trial did not reproduce cleanly: the paper reports a nominally significant difference between 5 mg and placebo on a percentage-of-baseline scale that was not robust to log transformation and is presented as exploratory.
  • WO2024168411A1, Food additive and/or food supplement, production method, formulation of functional food and/or food supplement, use(2024)
    The published patent application that ties the names together, cited for exactly that. It defines the peptide of sequence identifier 1 as Asp-Ile-Ile-Ala-Asp-Asp-Glu-Pro-Leu-Thr, or DIIADDEPLT, also known as Pep19 or WATACAP, in an application covering use as a food additive and food supplement. The effects it claims for feeding the peptide are attenuation of postprandial glycemia, reduced serum triglycerides and effects on liver function.
  • Proteimax, PEP19 product page(2026)
    The developer's own product page, read as a company document and cited for the claims it makes rather than as evidence for them. It describes Pep19 as the world's first naturally occurring peptide to restore metabolic health, states that it has undergone a self-affirmed GRAS process dated 2022, and in the same section calls it FDA-recognized. It gives the product as a 10 mg daily oral capsule and describes the mechanism as a browning-like effect in white fat together with improved insulin efficiency. No FDA GRAS notice inventory entry was located for this ingredient during this review.
  • NutraIngredients, Unpacking the multiple health claims of Pep19(2025)
    Trade press coverage of the first trial, read via a reproduction and used only for two statements it attributes to the developer: that the company notified the FDA regarding structure and function claims for Pep19, which is the dietary supplement notification route and is not an approval, and that the product became commercially available at a 5 mg dose.
  • Third-party copy of registry record NCT06359327, Effect of Consumption of Pep19 on Quality of Life(2024)
    The registry record for the 24-person trial, read via a third-party reproduction because ClinicalTrials.gov could not be opened during this review. It lists the sponsor as Proteimax Biotechnology Israel, 24 participants in three groups including placebo, interventions of Pep19 5 mg, Pep19 2 mg and placebo, and a masking of single blind. The published paper describes the same study as triple-blinded, so the registry entry and the publication do not agree on masking. The registry description also states the ingredient was certified generally recognized as safe at up to 3.8 grams per day.
  • ReBEC registration RBR-7jmj48v, supporting document(2025)
    A registered Brazilian trial of the same compound in fatty liver disease, cited to show what is underway and unpublished. The document is a letter of awareness and agreement from the company for a study at the Ribeirao Preto medical school titled, in Portuguese, the effect of supplementation with WATACAP (Pep19) on metabolic dysfunction-associated steatotic liver disease, assessed by magnetic resonance. It names the compound as WATACAP, Pep19, CAS 1536481-46-5, and is dated September 8, 2025. No results have been published.

Beyond these, 4 records are indexed for this compound. Browse the records